A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib - J2N-MC-JZNY

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2011240080

Enrollment

279

Registered

2025-03-28

Start date

2025-05-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Lymphocytic Leukemia Non-Hodgkin Lymphoma

Interventions

DRUG: Pirtobrutinib(Other Name: LOXO-305, LY3527727) Administered orally. (Study Arms) Experimental: JZ01 Pirtobrutinib Participants receive pirtobrutinib as defined in the originator study (LOXO

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are participating in an eligible Lilly sponsored clinical study evaluating pirtobrutinib.

Exclusion criteria

Exclusion criteria: Are pregnant, or intend to become pregnant during the study, or within 30 days of last dose of study treatment or to breastfeed during the study or within 1 week of the last dose of study treatment.

Design outcomes

Primary

Measure	Time frame
Percentage of Participants with a Grade >=3 treatment-emergent AEs [ Time Frame: Time from the Date of the First Dose of Study Intervention (Study Day 1) through 30 Days (+ 7-day window) After the Date of the Last Dose of Study Intervention or The First Date Starting a New Anticancer Therapy, whichever is Earlier	—

Countries

Australia, Japan

Contacts

Public ContactTrial Guide Call Center

Eli Lilly Japan K.K.

LTG_CallCenter@lists.lilly.com+81-120-023-812

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026